Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: schadenfreude who wrote (105)	10/6/1998 11:14:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

news, humanized monoclonals...... * CENTOCOR INC plans to launch Remicade, approved in August for treating Chrohn's disease, for the treatment of rheumatoid arthritis in late 1999 in the U.S. and the second half of 2000 in Europe. David Holveck, president and CEO of Centocor told investors that Remicade reached its first Crohn's disease patient late last week. Centocor plans to file for approval of the rheumatoid arthritis indication in the United States late this year or in the 1Q of 1999. Holveck repeated a previous statement that the company planned to announce data from Phase 3 studies for the rheumatoid arthritis indication in November. Holveck said the company plans to launch Remicade for Chrohn's disease in Europe in the first half of 1999. (Reuters 10:18 AM ET 10/06/98) and, from BGEN's sparkling release yesterday, anti-CD40L now has a name, "Antova" (thanks, Peter)......... Jim Tobin, Biogen's Chief Executive Officer, said....... "We continue to make excellent progress with our development pipeline, which includes AMEVIVE(TM) (human LFA-3/IgG fusion protein) for psoriasis, ANTOVA(TM) (humanized CD40 Ligand antibody/5c8) for autoimmune disease and CVT-124 for congestive heart failure. We have a number of clinical trials underway and will begin to have results of several Phase II trials in early 1999."